Clinical Trials Directory

Trials / Unknown

UnknownNCT05550766

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma: An Immunohistochemical Study.

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC \& BCC by using RXR-α biomarker \& attempts to use it in the treatment.

Conditions

Timeline

Start date
2022-12-01
Primary completion
2023-09-01
Completion
2023-12-01
First posted
2022-09-22
Last updated
2022-09-22

Source: ClinicalTrials.gov record NCT05550766. Inclusion in this directory is not an endorsement.

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma (NCT05550766) · Clinical Trials Directory